LATEST NEWS

This article originally appeared on our sister site, OncLive®. The FDA has granted accelerated approval to retifanlimab-dlwr (Zynyz) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).1. The regulatory decision is supported by data from the phase 2 POD1UM-201 trial (NCT03599713), in which...

Findings from 2 clinical trials support the approval of acalabrutinib as a treatment for patients with mantle cell lymphoma in China. China’s National Medical Products Administration has conditionally approved acalabrutinib (Calquence) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior line of therapy, according to a press release from AstraZeneca.1.

Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition. Background: Mitogen-activated protein kinase (MEK) inhibitors, which integrate the important signaling chain of the RAS-RAF-MEK-ERK1/2 pathway, regulate cell functions such as division and proliferation for patients with solid tumors. However, various ocular adverse effects (AEs) affect patients during clinical treatment. This systematic review aimed to assess the occurrence of AEs during treatment with MEK inhibitors plus targeted therapy or chemotherapy.

The custom integration (CI) industry is at a crossroads. The combined impact of technological advances, lower prices and greater public acceptance of digital tools have created enormous opportunities for integrators of all sizes and strengths, however the ever-prevalent talent shortage has made it so seizing those project opportunities has been a challenge.

If volatility wasn’t the big theme of the last week already, here comes the ETF Issuer League to underline it. While AUM news week to week tends to focus on the biggest firms and names, this week’s standout number came for Barclays Capital and its $1.8 billion AUM ETF suite. The firm’s ETFs added $132 million total over the last week, a 7% jump in AUM. That was the largest percentage spike in AUM for issuers larger than $1 billion, and much of it can be attributed to the VIX.

Molecular testing may be underused in patients with metastatic non-small cell lung cancer (NSCLC), according to a study published in Clinical Lung Cancer. Roughly half of patients in the study underwent molecular testing, and testing was associated with shorter time to systemic treatment. The study included 3600 patients from 8...

A number of other institutional investors and hedge funds have also bought and sold shares of CI. Axiom Financial Strategies LLC bought a new position in The Cigna Group during the first quarter valued at approximately $212,000. Fairfield Bush & CO. bought a new position in The Cigna Group during the first quarter valued at approximately $40,000. Cibc World Market Inc. grew its position in The Cigna Group by 52.6% during the first quarter. Cibc World Market Inc. now owns 18,975 shares of the health services provider’s stock valued at $4,547,000 after acquiring an additional 6,538 shares during the last quarter. Vontobel Holding Ltd. grew its position in The Cigna Group by 6.5% during the first quarter. Vontobel Holding Ltd. now owns 9,212 shares of the health services provider’s stock valued at $2,265,000 after acquiring an additional 566 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in The Cigna Group by 36.5% during the first quarter. Sequoia Financial Advisors LLC now owns 1,283 shares of the health services provider’s stock valued at $307,000 after acquiring an additional 343 shares during the last quarter. 87.61% of the stock is owned by hedge funds and other institutional investors.

Threats to critical infrastructure (CI) and the need for nation states to protect such assets have been brought to the fore with Russia’s invasion of Ukraine and its relentless attacks, both physical and via cyberspace, on the country’s vital assets. Critical infrastructure, the services and utilities essential to...

After a lengthy delay at the Durban High Court on Friday, March 24, the corruption and fraud trial of former eThekwini Mayor Zandile Gumede and 21 other defendants began at 2 o’clock in the afternoon. However, the court barely considered the issue for a few minutes before adjourning it until July 17th.

Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College. Treatment with first-line zolbetuximab (IMAB362) plus capecitabine and...

Hello! This article presents Soft Dashboard Tailwind, a premium Django started crafted with Docker Support, CI/CD, and full integration for Django Auth system and Admin Section reserved for superusers. For newcomers, Tailwind is a powerful CSS framework for coding user interfaces and Django is an actively supported backend used to code secure and scalable apps. Thanks for reading!

This month, the Fairwinds Insights release notes include helpful improvements and bug fixes in the Insights platform. We’re also very excited to share our Costs page updates, which are currently still in Beta (but going live soon). We’ve launched several excellent new features on the Costs page to help you make informed decisions about your costs, identify where spend is going, and get visualizations for recommendations.

Brian Mitzman, MD, FACS, FCCP, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer. Brian Mitzman, MD, FACS, FCCP, assistant professor, Division of Cardiothoracic Surgery, the University of Utah Huntsman Cancer Institute, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer (NSCLC).

Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy. Julie Renee Brahmer, MD, co-director, the Upper Aerodigestive Department,...

FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary. The anti-claudin 18.2 (CLDN18.2) monoclonal antibody zolbetuximab administered in combination with capecitabine and oxaliplatin (CAPOX) showed a statistically significant and clinically meaningful progression-free survival (PFS)...

Hybrid role (Weekly 2/3 days) • Experience with cloud platforms AWS( Auto scaling , AVI, security, EC2 , EFS , EBS , S3 , KMS) Hands on experience with CI/CD tools such as Jenkins, Ansible Working knowledge of monitoring tools like CA Wily, New Relic, and Datadog Experience with Elasticsearch, Kibana, and Logstash Execution on all release engineering aspects of DevOps including the configuration management , Build and Deployment Management, Continuous Integration and Delivery Ansible based deployment and configuration automation solutions.

Frailty is associated with mortality risk in patients undergoing emergency general surgery (EGS), with greater associations shown in patients undergoing low-risk EGS procedures, according to a recent study. The researchers conducted a cross-sectional study using data from 882,929 Medicare inpatient claims. Overall, 12.6% of the patients were considered frail, and...

A study shows differences in the ethno-racial presentation of of psoriasis. The results appeared in Dermatology Online Journal. “Skin of colored patients with psoriasis are more likely to remain undiagnosed and experience a greater impact on quality of life than their white counterparts. A better understanding of the ethno-racial differences in the presentation of psoriasis can help address these disparities,” the researchers said.